The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells

粘合连接 殖民地化 利基 乳腺癌 PI3K/AKT/mTOR通路 癌症研究 生物 癌症 钙粘蛋白 癌细胞 细胞生物学 信号转导 细胞 遗传学 微生物学 生态学
作者
Hai Wang,C. Ron Yu,Xia Gao,Thomas Welte,Aaron M. Muscarella,Lin Hai Tian,Hong Zhao,Zhen Zhao,Shiyu Du,Jianning Tao,Brendan Lee,Thomas F. Westbrook,Stephen T. C. Wong,Xin Jin,Jeffrey M. Rosen,Charles Kent Osborne,Xiang H.-F. Zhang
出处
期刊:Cancer Cell [Cell Press]
卷期号:27 (2): 193-210 被引量:410
标识
DOI:10.1016/j.ccell.2014.11.017
摘要

•Intrailiac artery injection allows studies of bone metastasis initiation•Bone micrometastases reside in the microenvironment niche with active osteogenesis•The niche cells boost tumor proliferation via adherens junctions (AJs)•The mTOR pathway lies downstream of AJs and mediates metastasis initiation Breast cancer bone micrometastases can remain asymptomatic for years before progressing into overt lesions. The biology of this process, including the microenvironment niche and supporting pathways, is unclear. We find that bone micrometastases predominantly reside in a niche that exhibits features of osteogenesis. Niche interactions are mediated by heterotypic adherens junctions (hAJs) involving cancer-derived E-cadherin and osteogenic N-cadherin, the disruption of which abolishes niche-conferred advantages. We elucidate that hAJ activates the mTOR pathway in cancer cells, which drives the progression from single cells to micrometastases. Human data set analyses support the roles of AJ and the mTOR pathway in bone colonization. Our study illuminates the initiation of bone colonization, and provides potential therapeutic targets to block progression toward osteolytic metastases. Breast cancer bone micrometastases can remain asymptomatic for years before progressing into overt lesions. The biology of this process, including the microenvironment niche and supporting pathways, is unclear. We find that bone micrometastases predominantly reside in a niche that exhibits features of osteogenesis. Niche interactions are mediated by heterotypic adherens junctions (hAJs) involving cancer-derived E-cadherin and osteogenic N-cadherin, the disruption of which abolishes niche-conferred advantages. We elucidate that hAJ activates the mTOR pathway in cancer cells, which drives the progression from single cells to micrometastases. Human data set analyses support the roles of AJ and the mTOR pathway in bone colonization. Our study illuminates the initiation of bone colonization, and provides potential therapeutic targets to block progression toward osteolytic metastases. In advanced stages, breast cancer bone metastases are driven by paracrine crosstalk among cancer cells, osteoblasts, and osteoclasts, which constitute a vicious osteolytic cycle. Current therapies targeting this process limit tumor progression, but do not improve patient survival. On the other hand, bone micrometastases may remain indolent for years before activating the vicious cycle, providing a therapeutic opportunity to prevent macrometastases. Here, we show that bone colonization is initiated in a microenvironment niche exhibiting active osteogenesis. Cancer and osteogenic cells form heterotypic adherens junctions, which enhance mTOR activity and drive early-stage bone colonization prior to osteolysis. These results reveal a strong connection between osteogenesis and micrometastasis and suggest potential therapeutic targets to prevent bone macrometastases. When diagnosed in the clinic, breast cancer bone metastases are primarily osteolytic and driven by a vicious cycle between cancer cells and osteoclasts (Ell and Kang, 2012Ell B. Kang Y. SnapShot: bone metastasis.Cell. 2012; 151: 690-690.e1Abstract Full Text PDF PubMed Scopus (82) Google Scholar, Kozlow and Guise, 2005Kozlow W. Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.J. Mammary Gland Biol. Neoplasia. 2005; 10: 169-180Crossref PubMed Scopus (271) Google Scholar, Mackiewicz-Wysocka et al., 2012Mackiewicz-Wysocka M. Pankowska M. Wysocki P.J. Progress in the treatment of bone metastases in cancer patients.Expert Opin. Investig. Drugs. 2012; 21: 785-795Crossref PubMed Scopus (35) Google Scholar, Mundy, 2002Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities.Nat. Rev. Cancer. 2002; 2: 584-593Crossref PubMed Scopus (2280) Google Scholar, Weilbaecher et al., 2011Weilbaecher K.N. Guise T.A. McCauley L.K. Cancer to bone: a fatal attraction.Nat. Rev. Cancer. 2011; 11: 411-425Crossref PubMed Scopus (884) Google Scholar). Bisphosphonates (Diel et al., 1998Diel I.J. Solomayer E.F. Costa S.D. Gollan C. Goerner R. Wallwiener D. Kaufmann M. Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.N. Engl. J. Med. 1998; 339: 357-363Crossref PubMed Scopus (772) Google Scholar) and denosumab (Lipton et al., 2007Lipton A. Steger G.G. Figueroa J. Alvarado C. Solal-Celigny P. Body J.J. de Boer R. Berardi R. Gascon P. Tonkin K.S. et al.Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.J. Clin. Oncol. 2007; 25: 4431-4437Crossref PubMed Scopus (321) Google Scholar) have been used to inhibit this vicious cycle and achieved a significant delay of metastasis progression, but they have not improved patient survival (Coleman et al., 2008Coleman R.E. Guise T.A. Lipton A. Roodman G.D. Berenson J.R. Body J.J. Boyce B.F. Calvi L.M. Hadji P. McCloskey E.V. et al.Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Clin. Cancer Res. 2008; 14: 6387-6395Crossref PubMed Scopus (55) Google Scholar, Mackiewicz-Wysocka et al., 2012Mackiewicz-Wysocka M. Pankowska M. Wysocki P.J. Progress in the treatment of bone metastases in cancer patients.Expert Opin. Investig. Drugs. 2012; 21: 785-795Crossref PubMed Scopus (35) Google Scholar, Onishi et al., 2010Onishi T. Hayashi N. Theriault R.L. Hortobagyi G.N. Ueno N.T. Future directions of bone-targeted therapy for metastatic breast cancer.Nat. Rev. Clin. Oncol. 2010; 7: 641-651Crossref PubMed Scopus (80) Google Scholar). Recent studies have elucidated roles for various pathways in osteolytic bone metastasis, including TGF-β, hypoxia, Hedgehog, Integrin, and Notch (Bakewell et al., 2003Bakewell S.J. Nestor P. Prasad S. Tomasson M.H. Dowland N. Mehrotra M. Scarborough R. Kanter J. Abe K. Phillips D. Weilbaecher K.N. Platelet and osteoclast beta3 integrins are critical for bone metastasis.Proc. Natl. Acad. Sci. USA. 2003; 100: 14205-14210Crossref PubMed Scopus (198) Google Scholar, Buijs et al., 2011Buijs J.T. Stayrook K.R. Guise T.A. TGF-β in the bone microenvironment: role in breast cancer metastases.Cancer Microenviron. 2011; 4: 261-281Crossref PubMed Scopus (55) Google Scholar, Dunn et al., 2009Dunn L.K. Mohammad K.S. Fournier P.G. McKenna C.R. Davis H.W. Niewolna M. Peng X.H. Chirgwin J.M. Guise T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.PLoS ONE. 2009; 4: e6896Crossref PubMed Scopus (178) Google Scholar, Heller et al., 2012Heller E. Hurchla M.A. Xiang J. Su X. Chen S. Schneider J. Joeng K.S. Vidal M. Goldberg L. Deng H. et al.Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment.Cancer Res. 2012; 72: 897-907Crossref PubMed Scopus (67) Google Scholar, Kang et al., 2003Kang Y. Siegel P.M. Shu W. Drobnjak M. Kakonen S.M. Cordón-Cardo C. Guise T.A. Massagué J. A multigenic program mediating breast cancer metastasis to bone.Cancer Cell. 2003; 3: 537-549Abstract Full Text Full Text PDF PubMed Scopus (2036) Google Scholar, Sethi et al., 2011Sethi N. Dai X. Winter C.G. Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells.Cancer Cell. 2011; 19: 192-205Abstract Full Text Full Text PDF PubMed Scopus (444) Google Scholar). Molecular and cellular events that initiate the vicious cycle have also been identified. Specifically, cancer-cell-derived and expressed VCAM-1 has been shown to engage osteoclast progenitor cells and accelerate their differentiation, which may represent a critical step for microscopic bone metastases to progress into clinically significant lesions (Lu et al., 2011Lu X. Mu E. Wei Y. Riethdorf S. Yang Q. Yuan M. Yan J. Hua Y. Tiede B.J. Lu X. et al.VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.Cancer Cell. 2011; 20: 701-714Abstract Full Text Full Text PDF PubMed Scopus (368) Google Scholar). These findings provide further therapeutic targets to intervene in the osteolytic cycle. In contrast to our knowledge of overt bone metastases, we know much less about microscopic bone metastases prior to the osteolytic cycle. In fact, such micrometastases may remain asymptomatic for a prolonged period of time before being reactivated to progress, a clinical phenomenon often referred to as metastasis dormancy (Aguirre-Ghiso, 2007Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy.Nat. Rev. Cancer. 2007; 7: 834-846Crossref PubMed Scopus (1191) Google Scholar). Disseminated tumor cells (DTCs) in the bone marrow have been detected in patients that appear tumor free (Pantel et al., 2008Pantel K. Brakenhoff R.H. Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells.Nat. Rev. Cancer. 2008; 8: 329-340Crossref PubMed Scopus (967) Google Scholar, Pantel et al., 2009Pantel K. Alix-Panabières C. Riethdorf S. Cancer micrometastases.Nat. Rev. Clin. Oncol. 2009; 6: 339-351Crossref PubMed Scopus (550) Google Scholar). DTCs may establish their first foothold in the bone marrow by competing with hematopoietic stem cells for the niche occupancy (Shiozawa et al., 2011Shiozawa Y. Pedersen E.A. Havens A.M. Jung Y. Mishra A. Joseph J. Kim J.K. Patel L.R. Ying C. Ziegler A.M. et al.Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.J. Clin. Invest. 2011; 121: 1298-1312Crossref PubMed Scopus (550) Google Scholar). However, it remains elusive how cancer cells interact with the niche cells to begin colonization and whether there are intermediate stages between solitary DTCs and osteolytic metastases. We used intrailiac artery (IIA) injection to monitor early-stage bone colonization. This approach selectively delivers cancer cells to hind limb tissues and bone through the external iliac artery (Figure 1A) without damaging local tissues. We characterized this approach and compared it to intracardiac (IC) injection, a widely used technique in bone metastasis research. Specifically, we examined the following: (1) the course of metastatic colonization, (2) organ distribution of disseminated tumor cells, and (3) the potential Darwinian selection process. Cell lines of different subtypes were analyzed to reveal the diverse metastatic behaviors of breast cancer cells. MDA-MB-231 cells (ER−/PR−/Her2−) are known to metastasize aggressively in xenograft models. Single cancer cells were readily detectable in the bone marrow immediately after IIA injection (Figure 1B). Strong bone lesions developed within 40 days, as indicated by the bioluminescence (BL) signals (Figure 1C). We stained the bone lesions for tartrate-resistant acid phosphatase (TRAP), a hallmark of activated osteoclasts, to ask if the lesions would progress fully. Positive staining was markedly increased compared to tumor-free counter-lateral legs of the same animals, indicating ongoing osteolytic cycle (Figure 1D). Compared to IC injection, cancer cells injected via IIA are predominantly localized to the hind limb bones, sparing lungs, the brain, and other soft tissue organs excessive tumor burdens (Figures 1E and 1F). A larger quantity of cancer cells (e.g., 5 × 105 MDA-MB-231 cells) can be injected through IIA without causing thrombosis-related deaths to animals (Figure 1F), a phenomenon often seen during IC injection. As a result of the highly targeted delivery of cancer cells, full body BL signals strongly correlated with those from dissected bones (Figure S1A available online). We then designed a clonal competition assay to ask if IIA-injected cancer cells encounter a Darwinian selection process. We admixed RFP-tagged parental MDA-MB-231 cells with a GFP-tagged bone-tropic clone MDA-MB-231 SCP28 (Minn et al., 2005Minn A.J. Kang Y. Serganova I. Gupta G.P. Giri D.D. Doubrovin M. Ponomarev V. Gerald W.L. Blasberg R. Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.J. Clin. Invest. 2005; 115: 44-55Crossref PubMed Scopus (566) Google Scholar) at a 1:1 ratio. In 2 weeks, the GFP+/RFP+ shifted dramatically from 1:1 to >10:1 (Figures 1G and S1B) in both IIA and IC models, reflecting the Darwinian selection process during bone colonization. We then examined MCF-7 cells (ER+/PR+/Her2−), a cell line experimentally more indolent than MDA-MB-231 cells. IIA injection delivered MCF-7 cells primarily to the hind limb. IC injection only resulted in detectable bone colonization in two of five mice, whereas IIA injection gave rise to bone lesions in all five animals examined (Figures S1C and S1D). The kinetics of MCF-7 bone colonization was slow in the first 2–4 weeks, but accelerated afterward (Figure 1H). We used an inducible H2B-GFP system to track the proliferation history of individual cells (Figure S1E; Fuchs and Horsley, 2011Fuchs E. Horsley V. Ferreting out stem cells from their niches.Nat. Cell Biol. 2011; 13: 513-518Crossref PubMed Scopus (71) Google Scholar). Although some cancer cells progressed to microscopic lesions in 2 weeks, a proportion stayed positive for H2B-GFP (Figure 1I). Ki67 staining on consecutive sections confirmed that these H2B-GFP+ cells were not proliferative (Figure 1I). Therefore, the fates of cancer cells vary after their arrival in the bone marrow. There was no enrichment of TRAP staining in or surrounding tumor lesions on day 28 or earlier (Figure 1J). Starting on day 35, some lesions showed increased TRAP staining, indicating a transition toward the osteolytic cycle (Figures 1J and 1K). We used this information to define a preosteolytic stage. The preosteolytic phase can be much longer in other models, such as MDA-MB-361 cells (ER+/PR+/Her2+), which did not exhibit increased TRAP signals until 4 months after IIA injection (Figures S1F and S1G) in a minority of mice (2 of 10). Taken together, these data show that IIA injection is useful to investigate the early stage of bone colonization prior to the osteolytic cycle. To ask if bone colonization initiation requires interactions with specific bone cells, we performed IIA injection of MCF-7 cells and MDA-MB-361 cells. We also examined 4T1 and 4TO7 cells into syngeneic BALB/c mice to include the competent immune system. In the preosteolytic stage, we conducted immunofluorescence (IF) staining of various cell type markers in conjunction with GFP (for MCF-7, 4T1, and 4TO7 cells) or Keratin 8 (for MDA-MB-361). We found that the niche cells express abundant alkaline phosphatase (ALP) and collagen-I (Col-I), markers of the osteoblast lineage (Figure 2A). In contrast, only a minority of lesions directly contacted CTSK+ osteoclasts (Figure 2A), and there were mostly fewer CTSK+ cells surrounding the microscopic lesions, confirming the preosteolytic status. We then quantitated niche composition. The niche was defined as the single layer of cells that directly contact bone lesions. We quantitated the following: (1) the frequency of each cell type relative to other cell types, and (2) the frequency of niches containing each cell type. First, ALP+ cells accounted for about 80% of niche cells, Col-I+ cells accounted for 40%–65%, and CTSK+ cells accounted for less than 20% (Figure 2B). The frequencies of ALP+ and Col-I+ cells were 10% and 3% in the tumor-free metaphysis area, suggesting enrichment of these cells in the niche. The absolute numbers of each cell type also were counted (Figure 2C), leading to the same conclusion. Second, we assessed the proportion of lesions that had at least two cells of each type in the niche (Figure 2D). All niches contained ALP+ and Col-I+ cells, strongly suggesting that these cells are associated with the progression to multicell lesions. CTSK+ cells were only found in a minority of niches in MCF-7, MDA-MB-361, and 4T1 models. In the 4TO7 model, CTSK+ cells were found in all niches examined with a relatively low frequency in each niche (Figures 2B and 2C). We also examined cells expressing Nestin, CD31, αSMA, and CD45 (Figure S2A). None of these cell types were nearly as frequent as ALP+ and Col-I+ cells. Taken together, these findings suggest that ALP+ and Col-I+ cells are the primary components of the microenvironment niche in early stage bone colonization. In contrast, the abundance of CTSK+ osteoclasts and other cell types in the niche is relatively minor. ALP and Col-I are associated with osteogenesis, or bone formation, and have been used as cell markers of osteoblasts (Lynch et al., 1995Lynch M.P. Stein J.L. Stein G.S. Lian J.B. The influence of type I collagen on the development and maintenance of the osteoblast phenotype in primary and passaged rat calvarial osteoblasts: modification of expression of genes supporting cell growth, adhesion, and extracellular matrix mineralization.Exp. Cell Res. 1995; 216: 35-45Crossref PubMed Scopus (336) Google Scholar, Pittenger et al., 1999Pittenger M.F. Mackay A.M. Beck S.C. Jaiswal R.K. Douglas R. Mosca J.D. Moorman M.A. Simonetti D.W. Craig S. Marshak D.R. Multilineage potential of adult human mesenchymal stem cells.Science. 1999; 284: 143-147Crossref PubMed Scopus (17938) Google Scholar). Several lines of evidence indicate that the niche of the microscopic lesions involves an active osteogenesis process. First, a variable proportion of the niche cells expressed RUNX2 and Osterix (Osx) (Figures 2E, 2F, and S2B), master regulators of osteogenesis. In contrast, the chondrogenesis regulator SOX9 was not detected in the niche (Figure 2G). Second, the niche cells displayed active canonical WNT signaling, as indicated by the nuclear localization of β-catenin (Figure 2H, open arrows) and LEF-1 expression (Figure S2C). WNT signaling is a major driving force of osteogenesis (Baron and Kneissel, 2013Baron R. Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments.Nat. Med. 2013; 19: 179-192Crossref PubMed Scopus (1389) Google Scholar, Long, 2012Long F. Building strong bones: molecular regulation of the osteoblast lineage.Nat. Rev. Mol. Cell Biol. 2012; 13: 27-38Crossref Scopus (777) Google Scholar). Of note, β-catenin was also observed along the membrane, suggesting adherens junctions (AJs) (Figure 2H, solid arrows). Third, histomorphometry analyses showed a 3- to 5-fold higher osteoid (newly formed osteoblasts) coverage in areas directly adjacent to the lesions (Figures 2I and 2J). In contrast, the osteoclast coverage was not affected (Figures 2J and S2D). Collectively, these findings strongly support that the osteogenesis process is associated with the niche of microscopic lesions. Therefore, we will use the term osteogenic niche to describe the microenvironment of early-stage bone colonization. To model the interaction with niche cells, we performed coculture assays using bone cells representing different stages of osteogenesis. Specifically, we used an immortalized human MSC cell line (Liu et al., 2011Liu S. Ginestier C. Ou S.J. Clouthier S.G. Patel S.H. Monville F. Korkaya H. Heath A. Dutcher J. Kleer C.G. et al.Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.Cancer Res. 2011; 71: 614-624Crossref PubMed Scopus (485) Google Scholar) and primary murine MSCs of BALB/c mice. We also used MC3T3 cells and FOB1.19 cells to represent more differentiated osteoblast precursor cells and osteoblasts, respectively. The osteogenesis capacity of some of these cells was validated in vitro (Figure S3A). To ask if cells from other lineages would have similar effects, we chose U937 and RAW264.7, two monocyte lines that can differentiate into osteoclasts. In 2D cultures, MSCs promoted cancer cell growth in a dose-dependent manner (Figure S3B). When the two cell types were separated using Boyden Chamber, the promoting effects were diminished (Figure S3C), suggesting the necessity of direct cell-cell contact. We next performed cocultures in 3D suspension conditions widely used in mammosphere assays. Interestingly, cancer cells and osteogenic cells formed a heterotypic organoid structure with an oncogenic shell and an osteogenic core (Figure 3A). This structure was not observed with the same cancer cells labeled with another color or with RAW264.7 cells (Figure 3A). Compared to the osteogenic niche structure in vivo (Figure 2A), the relative positioning (or polarity) of cancer and osteogenic cells was inverted in the heterotypic organoids. However, the organoids did recapitulate the extensive and direct contact between two cell types. Both MSC and FOB1.19 cells were able to accelerate tumor cell proliferation, with the effects increasing over time (Figure 3B). The effects of the monocytes were modest (Figure 3B), even after they differentiated into osteoclasts. Cancer cells in the heterotypic organoids exhibited a large increase of Ki67 staining, whereas the osteogenic cells in this structure appeared to differentiate with increased ALP expression (Figure 3C). The effects of MSCs on MCF-7 cells can be reproduced in a number of other cancer cell models as well as using more differentiated osteogenic cells (Figure 3D). To ask if osteogenic cells promote cancer cell proliferation in the bone microenvironment, we performed IIA injection using admixed cancer cells and osteogenic cells at a 1:1 ratio. Upon arrival at the bone marrow, about 50% of MCF-7 cells paired with MSCs via direct cell-cell contact (Figure 3E). The exogenous MSCs significantly decreased the latency and increased the tumor burden of bone colonization (Figures 3F and 3G). Similar results were also obtained using MDA-MB-361 cells (Figures 3H and S3D) and 4TO7 cells (Figure 3I). For the latter, the coinjection was performed on immunocompetent BALB/c mice. The direct and tight contact between microscopic lesions and the osteogenic niche led us to hypothesize that they form cell-cell junctions. The cancer cells used in previous experiments expressed variable levels of E-cadherin (E-cad) (Figure S4A). Interestingly, E-cad in cancer cells appears to be required for effects of osteogenic cells, as cancer cell lines without E-cad could not gain proliferative advantages from cocultured MSCs (Figure S4B). On the other hand, the osteogenic cells primarily expressed N-cadherin (N-cad) and OB-cadherin (OB-cad), but not E-cad. Since N-cad and E-cad have been reported to form heterotypic adherens junctions (E-N hAJs) in vitro (Straub et al., 2011Straub B.K. Rickelt S. Zimbelmann R. Grund C. Kuhn C. Iken M. Ott M. Schirmacher P. Franke W.W. E-N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells.J. Cell Biol. 2011; 195: 873-887Crossref PubMed Scopus (43) Google Scholar), we first focused on the interaction between these two cadherins. Several lines of evidence support the formation of E-N hAJs. First, costaining of E-cad and N-cad in heterotypic organoids confirmed that they are exclusively expressed in cancer cells and osteogenic cells, respectively, and are colocalized to the border of the two cell types (Figure 4A, arrows), where β-catenin is also localized (Figure 4B). Likewise, in the bone lesions, E-cad, N-cad, and β-catenin were aligned to the cancer-niche interface as well (Figures 4C and 2H). Second, a biochemical assay showed that E-cad was coimmunoprecipiated with N-cad, indicating that they physically interact with each other in vitro (Figure S4C). Third, a proximity ligation assay (PLA), which reflects molecular interaction in situ (Söderberg et al., 2006Söderberg O. Gullberg M. Jarvius M. Ridderstråle K. Leuchowius K.J. Jarvius J. Wester K. Hydbring P. Bahram F. Larsson L.G. Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation.Nat. Methods. 2006; 3: 995-1000Crossref PubMed Scopus (1754) Google Scholar), showed that E-cad and N-cad are colocalized in vitro and in microscopic bone lesions in vivo (Figures 4D and S4D). Costaining of N-cad and other markers revealed that N-cad is mainly expressed by ALP+ cells, but not CTSK+ cells, both in the niche of microscopic lesions (Figure 4E) and in the normal bone (Figure S4E). We also asked if endothelial cells are another major source of N-cad. However, endothelial cells only accounted for a minority of cells in the niche (Figure S2A) and only a small proportion of N-cad was colocalized with the endothelial cell marker, CD31 (Figure S4E). Taken together, these data strongly support that the E-N hAJ mediates the interaction between cancer cells and osteogenic cells in vitro and in vivo. In the clinic, bone metastases most frequently occur in tumors of the luminal subtype, which are typically ER+ (Kennecke et al., 2010Kennecke H. Yerushalmi R. Woods R. Cheang M.C. Voduc D. Speers C.H. Nielsen T.O. Gelmon K. Metastatic behavior of breast cancer subtypes.J. Clin. Oncol. 2010; 28: 3271-3277Crossref PubMed Scopus (1437) Google Scholar, Smid et al., 2008Smid M. Wang Y. Zhang Y. Sieuwerts A.M. Yu J. Klijn J.G. Foekens J.A. Martens J.W. Subtypes of breast cancer show preferential site of relapse.Cancer Res. 2008; 68: 3108-3114Crossref PubMed Scopus (582) Google Scholar). E-cad is the major cadherin in this subtype (Figure S4F; Perou et al., 2000Perou C.M. Sørlie T. Eisen M.B. van de Rijn M. Jeffrey S.S. Rees C.A. Pollack J.R. Ross D.T. Johnsen H. Akslen L.A. et al.Molecular portraits of human breast tumours.Nature. 2000; 406: 747-752Crossref PubMed Scopus (11662) Google Scholar, Sørlie et al., 2001Sørlie T. Perou C.M. Tibshirani R. Aas T. Geisler S. Johnsen H. Hastie T. Eisen M.B. van de Rijn M. Jeffrey S.S. et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc. Natl. Acad. Sci. USA. 2001; 98: 10869-10874Crossref PubMed Scopus (8513) Google Scholar). Our data suggest that E-cad in cancer cells mediates tumor-niche interaction, and might provide an explanation for the bone-tropism of luminal breast cancer. Expression of E-cad is weakly but significantly associated with worse overall survival and distant metastasis-free survival in the METABRIC (Curtis et al., 2012Curtis C. Shah S.P. Chin S.F. Turashvili G. Rueda O.M. Dunning M.J. Speed D. Lynch A.G. Samarajiwa S. Yuan Y. et al.METABRIC GroupThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.Nature. 2012; 486: 346-352Crossref PubMed Scopus (3694) Google Scholar) and Erasmus data sets (Smid et al., 2008Smid M. Wang Y. Zhang Y. Sieuwerts A.M. Yu J. Klijn J.G. Foekens J.A. Martens J.W. Subtypes of breast cancer show preferential site of relapse.Cancer Res. 2008; 68: 3108-3114Crossref PubMed Scopus (582) Google Scholar), respectively (Figure S4G). A further analysis revealed that E-cad is associated with bone metastasis specifically in the luminal subtype, which expresses a high level of E-cad (Figures 4F and S4F), but not in the basal subtype (Figures S4F and S4H). These results support the hypothesis that E-cad may mediate bone colonization if expressed in cancer cells, being the seeds of metastasis. On the other hand, the soil of bone metastasis, namely the bone and bone marrow, is largely E-cad low or negative (Figures 4C and S4I). The osteogenic cells including MSCs highly express N-cad and OB-cad (Figure S4A). Thus, if AJs are required for cancer cells to colonize the bone, they are likely to be constituted by E-cad of cancer cells and N-cad or OB-cad of osteogenic cells. The cadherin expression of human bone metastases retains the features of normal bone, in that N-cad and OB-cad are expressed at a higher level than metastases in other organs (Figure 4G). This suggests that metastatic bone lesions are heavily infiltrated by osteogenic cells. E-cad is expressed at a slightly lower level (Figure 4G), which is counterintuitive because cancer cells in bone metastases are mostly ER+ and expected to express E-cad (75% of bone metastases versus 47% of other metastases are ER+). A plausible explanation is that the infiltrated mesenchymal cells, rich in N-cad and OB-cad but scarce in E-cad, may dilute the overall level of E-cad of the entire lesion. Indeed, at the transcriptomic level, bone metastases exhibit mesenchymal characteristics, as reported in previous studies (Zhang et al., 2013Zhang X.H. Jin X. Malladi S. Zou Y. Wen Y.H. Brogi E. Smid M. Foekens J.A. Massagué J. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.Cell. 2013; 154: 1060-1073Abstract Full Text Full Text PDF PubMed Scopus (302) Google Scholar). Bone metastases also differ from other metastases in their enhanced expression of constitutive AJ components including α-catenin, β-catenin, and p120-catenin, suggesting the prevalence of AJ machinery (Figure 4H). Taken together, these data support the importance of AJs in human bone metastases. We used EGTA to titrate Ca2+ and disrupt AJs. At 1 mM, EGTA significantly decreased cancer cell proliferation in the heterotypic organoids, but had little effect on mammospheres formed by only cancer cells, suggesting a selectively more stringent dependence on Ca2+ of hAJs (Figure 5A). Antagonizing E-cad by a neutralizing antibody (anti-Ecad) or by inducible expression of dominant negative E-cad (DN-Ecad) (Nieman et al., 1999Nieman M.T. Kim J.B. Johnson K.R. Wheelock M.J. Mechanism of extracellular domain-deleted dominant negative cadherins.J. Cell Sci. 1999; 112: 1621-1632Crossref PubMed Google Scholar) both led to decreased cancer cell proliferation in the heterotypic organoids (Figures 5B, 5C, and S5A). We next perturbed N-cad in osteogenic cells by a neutralizing antibody (anti-Ncad) and siRNAs (si-Ncads). Both treatments resulted in

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
crescendo完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
3秒前
12完成签到,获得积分10
4秒前
ayzzdbr发布了新的文献求助10
5秒前
im羊完成签到 ,获得积分10
5秒前
Endeavor发布了新的文献求助10
5秒前
FY完成签到,获得积分20
5秒前
美丽冬卉完成签到,获得积分10
5秒前
所所的应助被lm采纳,获得10
6秒前
6秒前
领导范儿的应助被洋子采纳,获得10
6秒前
6秒前
7秒前
7秒前
111发布了新的文献求助10
7秒前
守护最好的坤坤完成签到,获得积分10
7秒前
张智磊发布了新的文献求助10
7秒前
8秒前
小棕瓶发布了新的文献求助10
8秒前
荼蘼发布了新的文献求助10
8秒前
牛牛牛发布了新的文献求助10
9秒前
木子李发布了新的文献求助10
9秒前
mt完成签到,获得积分10
10秒前
彬墩墩发布了新的文献求助10
12秒前
饽饽完成签到,获得积分10
12秒前
12秒前
ln发布了新的文献求助10
13秒前
内向问寒发布了新的文献求助30
13秒前
Dexter完成签到,获得积分10
13秒前
13秒前
吉吉国王完成签到,获得积分10
14秒前
14秒前
HMZ完成签到 ,获得积分10
14秒前
15秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241